Physician profile
Mohammad W Asfour
NPI 1275590283
$3,791.56
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $345 · 2021: $568 · 2022: $1,124 · 2023: $1,163 · 2024: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.80 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $407.58 | 2020-2023 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $331.16 | 2019-2024 | |
| Sk Life Science, INC. | $319.01 | 2021-2024 | |
| Harmony Biosciences LLC | $291.17 | 2021-2023 | Wakix |
| Abbvie INC. | $267.86 | 2019-2024 | Duopa, Qulipta |
| Teva Pharmaceuticals USA, INC. | $262.10 | 2019-2024 | Austedo Xr, Ajovy |
| Lilly USA, LLC | $213.76 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Jazz Pharmaceuticals INC. | $175.27 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $153.09 | 2022 | |
| Abbott Laboratories | $132.07 | 2021-2024 | Infinity |
| Ucb, INC. | $103.59 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $103.22 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $99.36 | 2023 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $87.52 | 2019-2023 | Rytary |
| Eisai INC. | $83.77 | 2022-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $77.30 | 2020 | |
| Kyowa Kirin, INC. | $69.56 | 2019-2022 | |
| Lundbeck LLC | $68.86 | 2020-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $54.47 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $47.63 | 2020-2022 | |
| Avion Pharmaceuticals | $46.14 | 2022-2023 | Dhivy |
| Pfizer INC. | $34.76 | 2023-2024 | |
| Upsher-Smith Laboratories LLC | $34.48 | 2020 | |
| Ani Pharmaceuticals, INC. | $30.83 | 2023 | Purified Cortrophin Gel |
| Amgen INC. | $30.23 | 2019-2022 | |
| Axsome Therapeutics, INC. | $29.47 | 2023 | Sunosi |
| Alexion Pharmaceuticals, INC. | $24.32 | 2023 | Ultomiris |
| Ge Healthcare | $21.04 | 2021 | |
| Argenx US, INC. | $20.71 | 2023 | Vyvgart |
| Corium, LLC | $19.43 | 2022 | |
| Allergan, INC. | $19.28 | 2020 | |
| Adamas Pharmaceuticals, INC. | $18.43 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.48 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $14.87 | 2022 | |
| Csl Behring | $14.74 | 2019 | |
| Acorda Therapeutics, INC | $13.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.87 | 2022 | |
| Alfasigma USA, INC. | $12.71 | 2021 | |
| Livanova USA, INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Asfour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.